These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 8837356)

  • 61. Changes in red cell ion transport, reduced intratumoral neovascularization, and some mild motor function abnormalities accompany targeted disruption of the Mouse Kell gene (Kel).
    Zhu X; Rivera A; Golub MS; Peng J; Sha Q; Wu X; Song X; Kumarathasan P; Ho M; Redman CM; Lee S
    Am J Hematol; 2009 Aug; 84(8):492-8. PubMed ID: 19544475
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Kell alloimmunization, hemolytic disease of the newborn, and perinatal management.
    Wenk RE; Goldstein P; Felix JK
    Obstet Gynecol; 1985 Oct; 66(4):473-6. PubMed ID: 3931011
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Novel alleles at the Kell blood group locus that lead to Kell variant phenotype in the Dutch population.
    Ji Y; Veldhuisen B; Ligthart P; Haer-Wigman L; Jongerius J; Boujnan M; Ait Soussan A; Luo G; Fu Y; van der Schoot CE; de Haas M
    Transfusion; 2015 Feb; 55(2):413-21. PubMed ID: 25156717
    [TBL] [Abstract][Full Text] [Related]  

  • 64. In vivo survival of K:18 red cells in a recipient with anti-K18.
    Barrasso C; Baldwin ML; Drew H; Ness PM
    Transfusion; 1983; 23(3):258-9. PubMed ID: 6679384
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Production and characterization of anti-kell monoclonal antibodies using transfected cells as the immunogen.
    Chu TH; Yazdanbakhsh K; Oyen R; Smart E; Reid ME
    Br J Haematol; 1999 Sep; 106(3):817-23. PubMed ID: 10468879
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Another example of mimicking anti-Kpb in a Kp(a+b-) patient.
    Puig N; Carbonell F; Marty ML
    Vox Sang; 1986; 51(1):57-9. PubMed ID: 3739324
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Immunochemical analysis of the Kx protein from human red cells of different Kell phenotypes using antibodies raised against synthetic peptides.
    Carbonnet F; Hattab C; Collec E; Le van Kim C; Cartron JP; Bertrand O
    Br J Haematol; 1997 Mar; 96(4):857-63. PubMed ID: 9074432
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The Day phenotype: a "new" variant in the Kell blood group system.
    Brown A; Berger R; Lasko D; Brokenshire D; Humphreys J; Stout T; Moore BP; Johnson CL; Mueller KA; Marsh WL
    Rev Fr Transfus Immunohematol; 1982 Dec; 25(6):619-27. PubMed ID: 7170568
    [No Abstract]   [Full Text] [Related]  

  • 69. Non-anti-D antibodies in red-cell alloimmunization.
    Moise KJ
    Eur J Obstet Gynecol Reprod Biol; 2000 Sep; 92(1):75-81. PubMed ID: 10986438
    [TBL] [Abstract][Full Text] [Related]  

  • 70. An autoanti-Kp b immunoglobulin M that simulates antigen suppression.
    Bosco A; Xenocostas A; Kinney J; Cadwell CM; Zimring JC
    Transfusion; 2009 Apr; 49(4):750-6. PubMed ID: 19170996
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The second example of anti-K22 and a family genetically informative for K and K22.
    Manny N; Levene C; Harel N; Schneiderman S; Simon A; Daniels GL
    Vox Sang; 1985; 49(2):135-7. PubMed ID: 4036083
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Investigation of monoclonal antibodies directed against Fy3, Jra, Lub, Kell or Kell related antigens.
    Janvier D; Veaux S; Benbunan M
    Transfus Clin Biol; 1997; 4(1):107-9. PubMed ID: 9095513
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Genetic and functional analyses describe a novel 730delG mutation in the KEL gene causing K0 phenotype in a Taiwanese blood donor.
    Yang MH; Li L; Kuo YF; Hung YS; Yu LC; Hung CS; Tsai SJ; Lin KS; Chu DC
    Transfus Med; 2011 Oct; 21(5):318-24. PubMed ID: 21707797
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Disulfide bonds are a requirement for Kell and Cartwright (Yta) blood group antigen integrity.
    Branch DR; Muensch HA; Sy Siok Hian AL; Petz LD
    Br J Haematol; 1983 Aug; 54(4):573-8. PubMed ID: 6871108
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Kell antibodies in pregnancy].
    Rempen A; Schweppe KW
    Z Geburtshilfe Perinatol; 1983; 187(4):183-90. PubMed ID: 6684844
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Current clinical management of anti-Kell alloimmunization in pregnancy.
    Santiago JC; Ramos-Corpas D; Oyonarte S; Montoya F
    Eur J Obstet Gynecol Reprod Biol; 2008 Feb; 136(2):151-4. PubMed ID: 17481801
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Obstetric outcome after RhD and Kell testing.
    Lipitz S; Many A; Mitrani-Rosenbaum S; Carp H; Frenkel Y; Achiron R
    Hum Reprod; 1998 Jun; 13(6):1472-5. PubMed ID: 9688374
    [TBL] [Abstract][Full Text] [Related]  

  • 78. IgG3 anti-Kell allotypic variation results in differential antigen binding and phagocytosis.
    Cen SY; Holton MB; Binnington B; Denomme GA; Howie HL; Lebedev JN; Zimring JC; Branch DR
    Transfusion; 2020 Apr; 60(4):688-693. PubMed ID: 31930726
    [TBL] [Abstract][Full Text] [Related]  

  • 79. An individual with McLeod syndrome and the Kell blood group antigen K(K1).
    Marsh WL; Schnipper EF; Johnson CL; Mueller KA; Schwartz SA
    Transfusion; 1983; 23(4):336-8. PubMed ID: 6879675
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The first example of autoanti-Kx.
    Sullivan CM; Kline WE; Rabin BI; Johnson CL; Marsh WL
    Transfusion; 1987; 27(4):322-4. PubMed ID: 2440157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.